ORIC Pharmaceuticals
ORIC Pharmaceuticals is a clinical‑stage oncology company developing targeted therapies intended to overcome mechanisms of treatment resistance in cancer. The business focuses on small molecules and biologics designed to restore or enhance tumour sensitivity to established treatments. As a clinical-stage developer, ORIC’s prospects are closely tied to trial outcomes, regulatory decisions and partner collaborations rather than stable commercial revenues. The company carries typical biotech risks: clinical and regulatory uncertainty, high research and development burn, and potential dilution from future financings. With a market capitalisation around $1.22 billion, the stock can be volatile around data readouts or corporate news. Investors should view ORIC as a higher‑risk, speculative exposure to oncology innovation and consider time horizon, diversification and risk tolerance. This information is educational and general in nature, not personalised investment advice; consider consulting a financial adviser before making investment decisions.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying ORIC Pharmaceuticals' stock with a target price of $20.42, indicating strong growth potential.
Financial Health
ORIC Pharmaceuticals shows good cash flow and book value, indicating solid financial performance.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring ORIC
Alternative Cancer Therapies Focus Shifts 2025
The FDA's new boxed warning for Johnson & Johnson and Legend Biotech's cancer drug highlights potential safety issues in CAR-T therapies. This could shift focus to companies developing alternative and potentially safer oncology treatments.
Published: October 13, 2025
Explore BasketFDA Cancer Warning: Beyond the Treatment Headlines
The FDA's new boxed warning for a major cancer therapy from Johnson & Johnson and Legend Biotech highlights the serious side effects of advanced treatments. This focus creates an investment opportunity in companies that develop drugs and therapies to help manage these adverse reactions, improving patient quality of life.
Published: October 12, 2025
Explore BasketOral Obesity Treatments: Beyond The Needle
Following successful Phase 3 trials for its oral weight-loss drug, orforglipron, Eli Lilly is positioned to enter the lucrative obesity treatment market. This development creates a new investment theme focused on pharmaceutical companies developing patient-friendly, oral alternatives to injectable GLP-1 therapies.
Published: August 27, 2025
Explore BasketPharma's Next Big Deal
This carefully curated group of stocks features promising biotech companies with valuable drug pipelines. These smaller firms could become the next targets for lucrative partnerships or acquisitions by pharmaceutical giants, similar to Glenmark's recent $2 billion deal with AbbVie.
Published: July 11, 2025
Explore BasketGarage Innovators
Meet the companies that are inventing tomorrow, today. These stocks represent businesses with exceptional in-house research and development, carefully selected by professional analysts for their ability to create breakthrough products and technologies from within.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Clinical catalysts ahead
Upcoming trial readouts and regulatory milestones can re‑rate the stock, though results are binary and can move the share price materially.
Focused oncology play
ORIC targets mechanisms of treatment resistance, a meaningful clinical need, but commercial success depends on proving benefit versus existing therapies.
Higher‑risk profile
As a clinical‑stage biotech with R&D burn and possible future financing, the stock may be volatile — suitable for investors comfortable with speculative risk.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ARCELLX, INC.
Develops T-cell therapies for the treatment of cancer.
AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
